Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis

Cost Effectiveness and Resource Allocation

Volumn 7, Issue , 2009, Pages

  Xie, Feng ^a,b   Blackhouse, Gord ^a,b   Assasi, Nazila ^a,b   Gaebel, Kathryn ^b   Robertson, Diana ^a,b   Goeree, Ron ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b Programs for Assessment of Technology in Health PATH Research Institute   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; COHORT ANALYSIS; COLON SURGERY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; OUTCOME ASSESSMENT; PATIENT CARE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; REMISSION; RESOURCE ALLOCATION; SENSITIVITY ANALYSIS; ULCERATIVE COLITIS;

EID: 73249153462     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/1478-7547-7-20     Document Type: Article

References (29)

1. Friedman S, Blumberg RS. Inflammatory bowel disease. Harrison's online 2008, Chapter 276. New York: McGraw-Hill Health Professions Division, Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, et al, 17, Accessed 2008 Feb 26.
2. Tremaine WJ. Refractory IBD: medical management. Neth J Med 1997, 50(2):S12-S14.
3. Wong JLH. Inflammatory bowel disease. Clinic handbook: gastroenterology, [electronic resource] 2002, Chapter 11. Abingdon (UK): Taylor & Francis.
4. Naber AH, de Jong DJ. Assessment of disease activity in inflammatory bowel disease; relevance for clinical trials. Neth J Med 2003, 61(4):105-10. Available: PM:12852718.
5. Remicade® e-CPS [database online]. 2008, Ottawa: Canadian Pharmacists Association.
6. Humira® e-CPS [database online]. 2008, Ottawa: Canadian Pharmacists Association.
7. Enbrel® e-CPS [database online]. 2007, Ottawa: Canadian Pharmacists Association.
8. Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, Vilien M, Strom M, Danielsson A, Verbaan H, Hellstrom PM, Magnuson A, Curman B. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005, 128(7):1805-11. 10.1053/j.gastro.2005.03.003, 15940615.
9. Probert CS, Hearing SD, Schreiber S, Kuhbacher T, Ghosh S, Arnott ID, Forbes A. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003, 52(7):998-1002. 10.1136/gut.52.7.998, 1773722, 12801957.
10. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353(23):2462-76. 10.1056/NEJMoa050516, 16339095.
11. Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, Podolsky DK. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001, 7(2):83-8. 10.1097/00054725-200105000-00001, 11383595.
12. Truelove SC, Witts JL. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955, 2(4947):1041-8. 10.1136/bmj.2.4947.1041, 1981500, 13260656.
13. Remicade. Notices of compliance [database online] 2007, Ottawa: Health Canada, Accessed 2008 Mar 13., http://www.hc-sc.gc.ca/dhp-mps/prodpharma/notices-avis/noc-acc/index_e.h tml
14. Common Drug Review CEDAC final recommendation and reasons for recommendation: plain language version. Humira® (adalimumab - Abbott Laboratories Ltd.) 2008, Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH).
15. Korzenik JR. Investigational therapies in the medical management of Crohn's disease. UpToDate [database online]. Waltham (MA): UpToDate 2007,
16. Oussalah A, Laclotte C, Chevaux JB, Bensenane M, Babouri A, Serre AA, Boucekkine T, Roblin X, Bigard MA, Peyrin-Biroulet L. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther 2008, 28(8):966-72. 10.1111/j.1365-2036.2008.03811.x, 18652603.
17. Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol 2007, 13(16):2328-32.
18. Ndegwa SL. Adalimumab for refractory Crohn's disease and ulcerative colitis [ACP Brief - Spring 2007 prioritization, FINAL] 2007, Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH).
19. Bernstein CN, Wajda A, Svenson LW, MacKenzie A, Koehoorn M, Jackson M, Fedorak R, Israel D, Blanchard JF. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 2006, 101(7):1559-68. 10.1111/j.1572-0241.2006.00603.x, 16863561.
20. New and Emerging Technology Briefing Infliximab (Remicade) for ulcerative colitis 2005, Birmingham (UK): National Horizon Scanning Centre (NHSC), Accessed 2008 Nov 11., http://www.pcpoh.bham.ac.uk/publichealth/horizon/outputs/documents/2005/ Infliximab.pdf
21. Arseneau KO, Sultan S, Provenzale DT, Onken J, Bickston SJ, Foley E, Connors AF, Cominelli F. Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis?. Clinical Gastroenterology & Hepatology 2006, 4(9):1135-42.
22. Hoie O, Wolters FL, Riis L, Bernklev T, Aamodt G, Clofent J, Tsianos E, Beltrami M, Odes S, Munkholm P, Vatn M, Stockbrugger RW, Moum B, . European Collaborative Study Group of Inflammatory Bowel Disease Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 2007, 132(2):507-15. 10.1053/j.gastro.2006.11.015, 17258717.
23. Fazio VW, Ziv Y, Church JM, Oakley JR, Lavery IC, Milsom JW, Schroeder TK. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg 1995, 222(2):120-7. 10.1097/00000658-199508000-00003, 1234769, 7639579.
24. Raval MJ, Schnitzler M, O'Connor BI, Cohen Z, McLeod RS. Improved outcome due to increased experience and individualized management of leaks after ileal pouch-anal anastomosis. Ann Surg 2007, 246(5):763-70. 10.1097/SLA.0b013e31814539b1, 17968167.
25. Alberta Health and Wellness Interactive Drug Benefit List 2009, Edmonton: Government of Alberta, Accessed 2009 Jan 19., https://www.ab.bluecross.ca/dbl/idbl_main1.html
26. Regie de l'assurance maladie du Quebec List of Medications 2008, Quebec: Gouvernement du Quebec, Accessed 2009 Jan 19., http://www.ramq.gouv.qc.ca/en/regie/lois/liste_med.shtml
27. Ontario Ministry of Health and Long-Term Care Schedule of benefits for physician services under the health Insurance Act 2008, Toronto: Queen's Printer for Ontario, Accessed 2008 Nov 11., http://www.health.gov.on.ca/english/providers/program/ohip/sob/physserv/ a_consul.pdf
28. Swenson BR, Hollenbeak CS, Koltun WA. Factors affecting cost and length of stay associated with the ileal pouch-anal anastomosis. Dis Colon Rectum 2003, 46(6):754-61. 10.1007/s10350-004-6653-7, 12794577.
29. Tsai HH, Punekar Y, Morris J, Fortun P. A model of the long-term cost-effectiveness of scheduled maintenance treatment with infliximab for moderate to severe ulcerative colitis. Aliment Pharmacol Ther 2008, 28(10):1230-9. 10.1111/j.1365-2036.2008.03839.x, 18729845.